《中国康复理论与实践》 ›› 2004, Vol. 10 ›› Issue (08): 500-501.

• 临床研究 • 上一篇    下一篇

雷洛昔芬治疗绝经后骨质疏松临床观察

翟建军; 殷佳仪; 张毅   

  1. 北京医院妇产科 北京市 100730
  • 收稿日期:2004-07-09 出版日期:2004-08-25 发布日期:2004-08-25

Effect of raloxifen on postmenopausal osteoporosis

ZHAI Jian-jun, YIN Jia-yi, ZHANG Yi   

  1. Department of Obstetric and Gynecology, Beijing Hospital, Beijing 100730, China
  • Received:2004-07-09 Published:2004-08-25 Online:2004-08-25

摘要: 目的观察选择性雌激素受体拮抗剂雷洛昔芬治疗绝经后骨质疏松症的疗效。方法66例绝经后骨质疏松症患者被随机分为观察组与对照组(各33例),前者服雷洛昔芬60mg/日,后者服安慰剂,治疗并观察6个月。治疗前后做常规化验检查,并行经阴道B超测量子宫内膜厚度及诊断性刮宫了解内膜情况。结果观察组腰椎、股骨颈及大粗隆、Ward’s的骨密度均升高,总有效率60.6%,明显高于对照组的21.2%(P<0.01);未见子宫内膜增生、内膜异常及阴道点状出血等。结论雷洛昔芬能明显提高绝经后骨质疏松症患者的骨密度,且不良反应轻微,无明显子宫内膜刺激等副作用。

关键词: 绝经后骨质疏松症, 雷洛昔芬, 骨密度

Abstract: ObjectiveTo observe the effect of raloxifen, a selective eastrogen receptor modulator, on postmenopausal osteoporosis.MethodsSixty six patients with postmenopausal osteoporosis were randomly divided into test group and control group with 33 cases in each group. Patients in the test group were treated with raloxifen (60 mg/day) for six months, at same time; cases in the control group were treated with placebo. Before and after treatment,routine laboratory examinations, transvaginal B type ultrasonic examination, and diagnostic curettage were performed. ResultsThe bone mineral densities of lumbar vertebrae and hip were significantly higher in the test group(60.6%) than in the control group(21.2%) (P<0.01). ConclusionRaloxifen is an effective medicine to treat postmenopausal osteoporosis, and it is also safe, without side effect of stimulating endometrim, etc.

Key words: postmenopausal osteoporosis, raloxifen, bone mineral density